{"product_id":"hims-bcg-matrix","title":"(HIMS) Hims \u0026 Hers Health, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Hims \u0026amp; Hers Health, Inc. BCG Matrix helps you see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs, making it useful for strategy, research, and capital allocation. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 weight loss\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGLP-1 weight loss is Hims \u0026amp; Hers Health, Inc.'s clearest Star: obesity care is a fast-growing market, and the company sells it through recurring telehealth and prescription fulfillment. In 2025, management kept expanding access while defending supply, which supports scale and repeat use. It needs heavy marketing and inventory support, but that is exactly what a Star demands.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMental health subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMental health subscriptions fit \"Stars\": Hims \u0026amp; Hers served 2.2 million subscribers in FY2024 and revenue rose 69% to $1.48 billion, showing strong demand. Mental health is still a large digital-care category with low penetration, and repeat visits plus ongoing medication management can lift lifetime value. With more investment, this line can keep scaling fast as adoption deepens.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrimary care visits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePrimary care visits are a strong entry point for Hims \u0026amp; Hers Health, Inc., because they bring users into the platform early and can lift repeat use across prescriptions, labs, and follow-up care. That matters in a category still moving online: Hims \u0026amp; Hers guided 2025 revenue to about $2.3 billion after 2024 revenue of $1.48 billion, showing scale and growth. In BCG terms, this fits a Star: high-growth demand with room to deepen wallet share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWomen’s health rollout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWomen’s health is a clear Stars segment for Hims \u0026amp; Hers: the Hers platform widens the audience beyond the male core and supports more repeat use through hormonal care, sexual health, and wellness. By FY2025, the company was still scaling at strong double-digit revenue growth, so this category can justify heavy spend on brand, paid media, and retention. Recurring care makes the lifetime value story stronger.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroadens the customer base beyond men\u003c\/li\u003e\n\u003cli\u003eDrives repeat prescriptions and visits\u003c\/li\u003e\n\u003cli\u003eSupports higher brand and channel spend\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInternational expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInternational expansion is a Star for Hims \u0026amp; Hers Health, Inc. because the long-term addressable market is much bigger than its U.S.-heavy base, which produced about $1.48 billion of revenue in 2024. Early non-U.S. penetration is still low, so today’s share is small, but that also leaves room for outsized growth if execution stays tight.\u003c\/p\u003e\n\n\u003cp\u003eThe 2024 ZAVA deal gave Hims \u0026amp; Hers a real foothold in the UK and parts of Europe, but overseas sales still trail the U.S. by a wide margin. That means this is not yet a cash engine, but it is a high-upside growth lane with room to scale.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLarge global demand base\u003c\/li\u003e\n\u003cli\u003eLow current international share\u003c\/li\u003e\n\u003cli\u003eStrong upside if execution holds\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHims \u0026amp; Hers’ Fastest-Growing Stars Are Driving the Next Growth Wave\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars for Hims \u0026amp; Hers Health, Inc. are the fastest-growing, recurring-care lines: GLP-1 obesity, mental health, primary care, and women’s health. FY2024 revenue was $1.48 billion, and management guided FY2025 revenue to about $2.3 billion, showing scale plus demand. These segments need heavy spend, but they can keep compounding through repeat prescriptions and visits.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar area\u003c\/th\u003e\n\u003cth\u003eFY2024\/FY2025 data\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGLP-1\u003c\/td\u003e\n\u003ctd\u003eKey growth driver\u003c\/td\u003e\n\u003ctd\u003eFast-growing market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMental health\u003c\/td\u003e\n\u003ctd\u003e2.2M subscribers\u003c\/td\u003e\n\u003ctd\u003eRecurring use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany\u003c\/td\u003e\n\u003ctd\u003e$1.48B to ~$2.3B\u003c\/td\u003e\n\u003ctd\u003eStrong growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eHims \u0026amp; Hers’ BCG matrix maps telehealth stars, cash-generating subscriptions, growth question marks, and low-share dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuick BCG view to spot Hims \u0026amp; Hers’ cash cows, stars, and drag, so teams can fix growth pain fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a credible source trail for Hims \u0026amp; Hers Health, Inc. that supports faster due diligence and more confident decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSildenafil and tadalafil\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSildenafil and tadalafil fit Hims \u0026amp; Hers Health, Inc. as a cash cow: ED is a mature, repeat-use category with low churn and known customer acquisition, while Hims \u0026amp; Hers ended 2024 with about 2.2 million subscribers and $1.5 billion in revenue. That scale lets the brand harvest steady cash from a well-known 30-day refill model with modest extra investment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinasteride hair-loss Rx\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFinasteride hair-loss Rx is one of Hims \u0026amp; Hers Health, Inc.'s most established recurring offers, built on a 1 mg daily dose and long-term use. Because patients often stay on therapy for months or years, it supports steady subscription cash flow. This makes it a cash cow: less about fast growth, more about monetizing an installed base. The business also benefits from low re-acquisition costs versus newer categories.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMinoxidil maintenance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMinoxidil maintenance is a low-complexity, repeat-fill hair-loss use case, so it behaves like a cash cow inside Hims \u0026amp; Hers Health, Inc.'s platform. Hair loss is a familiar problem, which supports steady reorders and low servicing cost. That matters at scale: Hims \u0026amp; Hers reported about $1.5 billion in FY2024 revenue and over 2 million subscribers, giving this category a strong margin base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSkincare subscriptions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSkincare subscriptions fit Hims \u0026amp; Hers Health, Inc.’s Cash Cow role because moisturizers, serums, and cleansers are familiar, repeatable, and easy to reorder. The subscription model keeps demand steady, so the line can keep generating cash without heavy product reinvention.\u003c\/p\u003e\n\u003cp\u003eIt also scales better than newer care categories, since the same routine products can be sold to a wider base with low added complexity. That makes skincare a useful profit pool while Hims \u0026amp; Hers Health, Inc. keeps investing in faster-growing offers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat buys support stable cash flow.\u003c\/li\u003e\n\u003cli\u003eSimple products lower selling friction.\u003c\/li\u003e\n\u003cli\u003eLow reinvention need keeps costs down.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWellness supplements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eWellness supplements fit Cash Cows because vitamins and supplements are a stable add-on, easy to bundle into recurring orders, and they lift basket size. In Hims \u0026amp; Hers Health, Inc.'s 2025 mix, this kind of repeat, low-friction SKU can support cash conversion even if growth trails newer care lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStable add-on demand\u003c\/li\u003e\n\u003cli\u003eBoosts recurring order value\u003c\/li\u003e\n\u003cli\u003eSlower growth, solid cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHims’ Cash Cows: Repeat-Use Prescriptions Drive $1.5B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSildenafil,tadalafil,finasteride,minoxidil,and skincare stay Hims \u0026amp; Hers Health,Inc.'s cash cows: mature,repeat-use offers with low churn and low re-acquisition cost. FY2024 revenue was about $1.5B and subscribers topped 2.2M, so these lines keep producing cash more than growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash cow\u003c\/th\u003e\n\u003cth\u003eWhy\u003c\/th\u003e\n\u003cth\u003e2024 scale\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\u003ctr\u003e\n\u003ctd\u003eED,hair loss,skincare\u003c\/td\u003e\n\u003ctd\u003eRepeat fills,steady demand\u003c\/td\u003e\n\u003ctd\u003e$1.5B;2.2M subs\u003c\/td\u003e\n\u003c\/tr\u003e\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eGet Your Copy\u003c\/span\u003e\u003cbr\u003eHims \u0026amp; Hers Health, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eYou’re previewing the exact Hims \u0026amp; Hers Health, Inc. BCG Matrix document you’ll receive after purchase. What you see here is the final, fully formatted file—no demo pages or hidden changes. Once purchased, it’s ready to download, edit, print, or share right away.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWholesale partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWholesale partnerships sit outside Hims \u0026amp; Hers Health, Inc.’s core direct-to-consumer subscription model, so they usually score as a Dog in the BCG Matrix. They cut control over pricing, customer data, and auto-renew billing, which weakens lifetime value versus the company’s $1.48 billion 2024 revenue engine built on direct recurring sales. That makes wholesale a low-fit, low-leverage channel.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-time OTC devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOne-time OTC devices fit Hims \u0026amp; Hers Health, Inc. as a Dogs asset in a BCG view: they bring one sale, not a repeat bill, so lifetime value stays below subscription plans. They also need more inventory and working capital, which hurts capital use when the model is built on recurring care. In 2025, the company’s growth remained subscription-led, so low-repeat OTC devices look like a lower-priority use of cash.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommodity cosmetics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCommodity cosmetics sit in the Dogs bucket because they are easy to copy, widely available, and highly price sensitive. Hims \u0026amp; Hers Health, Inc. can’t defend these SKUs with brand alone, so share and growth stay modest versus higher-margin wellness and prescription lines. In a market with thousands of near-identical products, even strong digital reach does not create a moat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-frequency accessories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLow-frequency accessories fit Hims \u0026amp; Hers Health, Inc. as Dogs in the BCG matrix: they are bought rarely, create little repeat demand, and do not meaningfully raise retention. The core business is still recurring digital care, while accessories stay a small add-on with limited strategic pull.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare purchases, weak repeat demand\u003c\/li\u003e\n\u003cli\u003eLittle retention lift\u003c\/li\u003e\n\u003cli\u003eEffort can exceed payoff\u003c\/li\u003e\n\u003cli\u003ePriority stays on recurring care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNon-core retail add-ons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-core retail add-ons are classic Dogs: low-share, low-growth items that add catalog clutter but very little profit or moat. Hims \u0026amp; Hers Health, Inc. is still driven by its subscription model; the core business generated about $1.48 billion in 2024 revenue, so small add-ons are unlikely to move the needle.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth, low strategic value\u003c\/li\u003e\n\u003cli\u003eWeak moat-building impact\u003c\/li\u003e\n\u003cli\u003eCan distract from core subscriptions\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThese items may help basket size a bit, but they do not scale like recurring care plans. In BCG terms, they fit the Dogs quadrant because share is small and growth contribution is limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHims \u0026amp; Hers’ Low-Value “Dog” Products Drag on Retention\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs at Hims \u0026amp; Hers Health, Inc. are low-repeat, low-control items like wholesale, OTC devices, cosmetics, and accessories. They do little for retention or pricing power, while the core model still centered on about $1.48 billion revenue in 2024 from recurring direct-to-consumer subscriptions.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDog item\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesale\u003c\/td\u003e\n\u003ctd\u003eLow control, weak data, low LTV\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOTC devices\u003c\/td\u003e\n\u003ctd\u003eOne-time sale, no repeat billing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCosmetics\u003c\/td\u003e\n\u003ctd\u003eEasy to copy, price sensitive\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccessories\u003c\/td\u003e\n\u003ctd\u003eRare buys, little retention lift\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMenopause and HRT\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMenopause and HRT is a Question Mark for Hims \u0026amp; Hers Health, Inc.: the addressable women’s-health market is large, with about 6,000 U.S. women reaching menopause each day, but digital penetration is still early. That leaves Hims \u0026amp; Hers with limited share today, even as demand for access and convenience rises. It needs continued investment in product, care delivery, and marketing to see if it can scale into a leader.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFertility care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFertility care fits the Question Mark bucket: demand is real, with 432,641 U.S. ART cycles reported by the CDC in 2022, and patients often pay out of pocket. Still, digital fertility is a small slice of a large market, so Hims \u0026amp; Hers Health, Inc. has an attractive growth path but limited proof at scale. If conversion and retention hold, it can move toward a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLab testing diagnostics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLab testing diagnostics is still a Question Mark for Hims \u0026amp; Hers Health, Inc.: it can lift medical utility and retention, but adoption is still early. The category only becomes strategic if it turns one-off tests into repeat use, since that feeds recurring care. In 2025, the real test is conversion, not scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChronic disease management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChronic disease management is a Question Mark for Hims \u0026amp; Hers Health, Inc.: metabolic health demand is rising fast, with the World Health Organization saying 1 in 8 adults had obesity in 2022, but the company still needs proof it can win beyond core telehealth categories. If it scales trusted care, this could turn into a Star; if not, capital should be reallocated.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth, weak share\u003c\/li\u003e\n\u003cli\u003eCredibility still being built\u003c\/li\u003e\n\u003cli\u003eInvest or walk away\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eB2B employer care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eB2B employer care gives Hims \u0026amp; Hers Health, Inc. a much larger route to users, but it is still a small part of the business. With 2.4 million subscribers and $1.48 billion in 2024 revenue, employer-led care is not yet the main engine, so this fits a Question Mark: big upside, low share.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eLarge channel, low current share\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eStrong growth option, high execution risk\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNeeds proof on repeat demand\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHims \u0026amp; Hers' Big Bets Need Proof\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks in Hims \u0026amp; Hers Health, Inc. are early-stage growth bets: menopause, fertility, lab testing, chronic disease, and employer care all have big markets but still low share. Hims \u0026amp; Hers Health, Inc. had 2.4 million subscribers and $1.48 billion revenue in 2024, but these lines need proof of repeat use and scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWomen’s health\u003c\/td\u003e\n\u003ctd\u003eLarge demand\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFertility\u003c\/td\u003e\n\u003ctd\u003e432,641 ART cycles\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234435145993,"sku":"hims-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/hims-bcg-matrix.webp?v=1785720857","url":"https:\/\/dcfanalyst.com\/products\/hims-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}